In vitro: PGE2 shows inhibition of IL 2 production in the mixture of irradiated and nonirradiated T lymphocytes. PGE2 (0.1-10 μM) dose-dependently inhibits the production of IL 2. PGE2 acts during the inductive phase of activation of suppressor cells. Preincubation of T lymphocytes with PGE2 induces cells that suppress IL 2 production and PHA proliferation. In vivo: PGE2 (0.3 μg/k, i.p.) significantly reduces the number of peritoneab macrophages undergoing phagocytosis of the methacrybate microbeads in rats. PGE2 (0.1 mg/min, i.a.) increases renal blood flow. PGE2 produces a biphasic change in renal vascular resistance, vasodilatation starts at 0.01 mg/min and is maximal at about 3 mg/min, while at the highest dose used (20 mg/min) PGE2 induces renal vasoconstriction.
|Cell lines||ovulatory follicles|
|Preparation method||All cells and tissues were obtained after ovarian stimulation before (0 h) and 12, 24, or 36 h after administration of an ovulatory dose of hCG.|
|Incubation time||12, 24, or 36 h|
|Animal models||male dogs|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO: ≥ 60 mg/mL|
Novel contraceptive targets to inhibit ovulation: the prostaglandin E2 pathway
Diane M, et al. Hum Reprod Update. 2015 Sep;21(5): 652–670. PMID: 26025453.
Changes in prostaglandin E2 levels in seminal plasma during ejaculation and the effect of exogenous prostaglandin E2 on semen volume in the dog.
Kobayashi M, et al. J Vet Med Sci. 2013;75(9):1249-52. PMID: 23629017.
|Related Prostaglandin Receptor Products|
TG4-155 is a brain penetrant prostaglandin EP2 specific antagonist, with a Ki of 9.9 nM.
PF-04418948 is a novel, potent and selective prostaglandin EP2 receptor antagonist with IC50 of 16 nM.
Fevipiprant (QAW039) is a selective, potent, reversible competitive CRTh2 antagonist.
Grapiprant is a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties.
E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM, exhibiting anti-tumor activities.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.